欧洲分子即时诊断检测(使用 NAAT)市场 – 行业趋势和 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

欧洲分子即时诊断检测(使用 NAAT)市场 – 行业趋势和 2028 年预测

  • Medical Devices
  • Published Report
  • Aug 2022
  • Europe
  • 350 页面
  • 桌子數: 137
  • 图号: 43

欧洲分子即时诊断检测(使用 NAAT)市场,按产品(仪器和消耗品及试剂)、适应症(呼吸道感染检测、性传播感染 (STI)检测、胃肠道感染检测等)、最终用户(实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等)、检测模式(基于处方的检测和 OTC 检测)、分销渠道(医院药房、零售药房和网上药房)– 行业趋势和预测到 2028 年。

分子诊断即时检测(使用 NAAT)市场

欧洲分子诊断即时检测(使用 NAAT)市场分析与洞察

欧洲分子即时检测(使用 NAAT)市场预计将实现增长,这是因为医疗设施和基础设施不断改善,医院、实验室和诊所采用即时检测,从而推动市场发展。预计推动分子即时检测(使用 NAAT)市场增长的其他因素包括传染病患病率不断上升。

分子诊断即时检测(使用 NAAT)市场

分子诊断即时检测(使用 NAAT)市场

其他因素,例如缺乏熟练的专业人员和定制分子即时检测(使用 NAAT)的高成本,阻碍了欧洲分子即时检测(使用 NAAT)市场的增长。另一方面,医疗支出的增加和拥有发达医院的新兴国家为欧洲分子即时检测(使用 NAAT)市场的增长提供了机会。

Data Bridge Market Research 分析,欧洲分子即时诊断(使用 NAAT)市场从 2021 年到 2028 年将以 10.8% 的复合年增长率增长。

报告指标

细节

预测期

2021 至 2028 年

基准年

2020

历史岁月

2019

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

按产品(仪器和耗材及试剂)、适应症(呼吸道感染检测、性传播感染 (STI) 检测、胃肠道感染检测等)、最终用户(实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等)、检测方式(处方检测和非处方药检测)、分销渠道(医院药房、零售药房和网上药房)

覆盖国家

英国、德国、法国、意大利、西班牙和欧洲其他地区

涵盖的市场参与者

SD Biosensor, Inc.、Abbott、F.Hoffmann-La Roche Ltd.、Danaher、Thermo Fisher Scientific Inc、binx Health, Inc.、Lucira、Meridian Bioscience、Quantumdx Group Ltd.、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Bio-Rad Laboratories, Inc.、Sekisui Diagnostic、Randox Laboratories Ltd.、GenMark Diagnostics、Seegene Inc. Grifols SA、Wondfo、Oxford Nanopore Diagnostic 和 PerkinElmer Inc.

欧洲分子诊断即时检测(使用 NAAT)市场定义

POCT 的特点是可以在患者附近进行检测,可以立即做出医疗决策,包括结果和监测。目前进入临床使用的 POCT 设备基于核酸扩增技术 (NAAT),本文将其定义为第二代设备。与第一代 POCT 相比,这些平台的灵敏度通常提高 60% 到 90%,并且需要便携式仪器,占地面积约为 30 厘米 x 30 厘米。这些仪器主要用于通过 NAAT 技术对各种疾病进行分子检测,例如 HIV、HPV 和呼吸系统疾病。NAAT 是核酸扩增技术,可通过检测病原体的 DNA 或 RNA 来识别病原体。

在全球大流行中,为了协同提高 NAAT 的灵敏度和 POCT 检测的易用性,设计了基于微型 NAAT 的 POCT 设备和检测,以更快地筛查和诊断 COVID-19,这也推动了市场的增长。

欧洲分子诊断即时检测(使用 NAAT)市场动态

 本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容:

驱动程序

  • 增加慢性病的患病率

众所周知,健康衰退始于年龄的增长。随着慢性病的发病率随时间推移而增长,与发病率相关的因素也随之增加。肥胖/超重人口数量众多也增加了全球各个地区慢性病的患病率。HPV、STI 和 TB 等慢性病数量的增加,导致人们选择基于 NAAT 的即时检测和产品进行检测。因此,这将在未来几年推动欧洲分子即时检测(使用 NAAT)市场的发展。

  • 诊断率提高

随着癌症、贫血、二型糖尿病等慢性病的成功诊断率不断提高,医疗专业人员的素质不断提高,定期为专业人员提供检测培训,以提高该地区的诊断率。随着疾病负担的增加,诊断率也在提高。随着诊断技术的进步,接受诊断的人数也在增加。

  • 家庭护理检测的偏好上升

家庭医疗保健偏好使临床信息可以在正确的时间和地点获得。它还将有助于减少错误并在确保质量的情况下提高安全性。它们还可以在发生医疗紧急情况时为老年人提供帮助。医疗保健领域已经进行了许多战略性变革,以解决即时检测的好处。根据世界卫生组织 (WHO) 的数据,65 岁及以上人口的数量预计将从 2010 年的 5.24 亿增加到 2050 年的约 15 亿,其中发达国家占增长的大部分。

机会

  • 市场参与者采取的战略举措

全球慢性和非慢性疾病负担的增加,加上非洲和亚洲老年人口的增加,对开发新试剂盒和分子即时检测解决方案的需求越来越大,这些试剂盒和解决方案具有更好的功效和更少的耗时。为了在该地区提供诊断和筛查,市场参与者相互合作并达成协议,通过试剂盒和仪器为欧洲人口提供优质护理。

  • 风险健康医疗支出

增加医疗支出和基础设施可以帮助患者轻松接受先进治疗,从而获得更好的诊断、手术和治疗,以快速康复。即时检测设备有利于检测各种疾病,并使用即时检测软件和解决方案支持治疗计划。医疗支出包括自付费用(人们支付医疗费用)、政府支出以及医疗保险和非政府组织活动等来源。

限制/挑战

  • 产品成本高

即时检测产品的开发过程需要相当可观的成本。由于需要确定概念,必须采购材料,并且必须考虑交货时间。此外,这个过程非常耗时,因为设备设计需要足够的时间才能完全成熟,然后才能投入市场使用。

  • 与实验室检测结果不一致

与实验室检测标准的结果相比,NAAT 检测结果有所不同。实验室检测更先进,遵循实验室检测的流程、协议和科学,并完全集成了准确分析、验证和记录效果所需的技术。然而,POCT/NAAT 无疑与缺乏精确的结果有关。分子 POCT 无法完成标准化,其他关键标准无法实现标准化和不同的基本标准。这对欧洲分子即时检测市场来说是一个重大挑战。PoC 测试有时会提供错误的结果,并且测试结果存在差异。

COVID-19 对欧洲分子即时诊断检测(使用 NAAT)市场的影响

COVID-19 严重影响了分子即时检测(使用 NAAT)市场。由于在线销售的不断增长和技术的进步,COVID-19 在更高水平上对分子即时检测(使用 NAAT)产品的价格和需求产生了积极影响。COVID-19 大流行的爆发对市场的增长产生了积极影响,因为对分子即时检测(使用 NAAT)的需求增加,尤其是在各家医院。由于 COVID-19 病例的激增仍在持续,大多数医院目前优先考虑 COVID-19 治疗,这也增加了分子即时检测(使用 NAAT)的使用。此外,许多国际政府和医疗保健组织都支持这些产品的供应,因为它们在危急情况下具有高度优先性。

最新动态

  • 2021 年 11 月,罗氏公司宣布,罗氏连续第十三年被评为道琼斯可持续发展指数中最具可持续性的三大医疗保健公司之一。这增加了预测期内的业务能力和业务扩张
  • 2021 年 10 月,赛默飞世尔科技公司获得 FDA 批准,用于 TaqMan COVId-19 检测 SARS-COV 分子检测。这增加了公司的产品组合,并在预测期内为公司收入做出了贡献

欧洲分子即时诊断检测(使用 NAAT)市场范围

欧洲分子即时检测(使用 NAAT)市场根据产品、适应症、最终用户、检测方式和分销渠道分为五个显著的细分市场。这些细分市场之间的增长将有助于分析行业中的市场增长细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

产品

  • 仪器
  • 耗材和试剂

根据产品,欧洲分子诊断即时检测(使用 NAAT)市场分为仪器、消耗品和试剂。

指征

  • 性传播感染 (STI) 检测
  • 呼吸道感染检测
  • 胃肠道感染检测
  • 其他的

根据适应症,欧洲分子诊断即时检测(使用 NAAT)市场分为性传播感染 (STI)、呼吸道、胃肠道和其他。

最终用户

  • 实验室
  • 医院
  • 诊所
  • 流动中心
  • 家庭护理
  • 辅助生活设施
  • 其他的

根据最终用户,欧洲分子即时诊断(使用 NAAT)市场分为实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等。

测试方式

  • 基于处方的测试
  • OTC测试

根据测试模式,欧洲分子诊断即时检测(使用 NAAT)市场分为处方检测和 OTC 检测

分销渠道

  • 医院药房
  • 零售药店
  • 网上药店

分子诊断即时检测(使用 NAAT)市场

根据分销渠道,欧洲分子诊断即时检测(使用 NAAT)市场分为医院药房、零售药房和在线药房。

欧洲分子诊断即时检测(使用 NAAT)市场区域分析/见解

对欧洲分子诊断即时检测(使用 NAAT)市场进行了分析,并根据产品、适应症、最终用户、检测模式和分销渠道提供了市场规模洞察和趋势。

欧洲分子诊断即时检测(使用 NAAT)市场报告涵盖英国、德国、法国、意大利、西班牙和欧洲其他地区。

就市场份额和市场收入而言,英国在欧洲分子即时检测(使用 NAAT)市场占据主导地位。在预测期内,英国将继续保持主导地位。这是由于传染病和慢性病的发病率不断上升,以及医疗保健领域的技术进步不断加快。

竞争格局和欧洲分子诊断即时检测(使用 NAAT)市场份额分析

欧洲分子即时检测(使用 NAAT)市场竞争格局提供了有关竞争对手的详细信息。 其中包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、公司优势和劣势、产品发布、监管指南、品牌分析、产品批准、产品有效载荷、应用主导地位、技术生命线曲线。 以上提供的数据点仅与公司对欧洲分子即时检测(使用 NAAT)市场的关注有关。

欧洲分子即时诊断检测(使用 NAAT)市场的一些主要参与者包括 SD Biosensor, Inc.、Abbott、F.Hoffmann-La Roche Ltd.、Danaher、Thermo Fisher Scientific Inc、binx Health, Inc.、Lucira、Meridian Bioscience、Quantumdx Group Ltd.、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Bio-Rad Laboratories, Inc.、Sekisui Diagnostic、Randox Laboratories Ltd.、GenMark Diagnostics、Seegene Inc. Grifols SA、Wondfo、Oxford Nanopore Diagnostic 和 PerkinElmer Inc. 等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DISTRIBUTION CHANNEL LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES

4.3.1 CEPHEID

4.3.2 THERMO FISHER SCIENTIFIC INC.

4.3.3 HOLOGIC, INC.

4.3.4 BD

4.3.5 F. HOFFMANN-LA ROCHE LTD

4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY

4.5 DISTRIBUTORS

4.5.1 NORTH AMERICA

4.5.2 EUROPE

4.5.3 SOUTH ASIA

4.5.4 SOUTH EAST ASIA

4.5.5 MIDDLE EAST

4.5.6 AFRICA

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

6.1.2 IMPROVING DIAGNOSIS SEEKING RATE

6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS

6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE

6.1.5 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 PRODUCT RECALLS

6.2.2 HIGH COSTS OF PRODUCTS

6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 PANDEMIC OUTBREAK OF COVID-19

6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 LACK OF ACCESSIBILITY

7 IMPACT OF COVID-19 ON THE EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19

7.5 CONCLUSION:

8 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & REAGENTS

8.3 INSTRUMENTS

8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)

8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)

9 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS TESTING

9.2.1 COVID-19

9.2.2 FLU B

9.2.3 FLU A

9.2.4 RSV

9.2.5 TUBERCULOSIS

9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)

9.2.7 OTHERS

9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING

9.3.1 TV

9.3.2 CT

9.3.3 NG

9.3.4 HPV

9.3.5 HSV

9.3.6 MG

9.3.7 UU

9.3.8 MH

9.3.9 OTHERS

9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING

9.4.1 GROUP B STREPTOCOCCUS

9.4.2 SHIGA TOXIN

9.4.3 H. PYLORI

9.5 OTHERS

10 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER

10.1 OVERVIEW

10.2 LABORATORIES

10.2.1 POLYMERASE CHAIN REACTION

10.2.2 ISOTHERMAL AMPLIFICATION

10.3 HOSPITAL

10.3.1 POLYMERASE CHAIN REACTION

10.3.2 ISOTHERMAL AMPLIFICATION

10.4 CLINICS

10.4.1 POLYMERASE CHAIN REACTION

10.4.2 ISOTHERMAL AMPLIFICATION

10.5 AMBULATORY CENTER

10.5.1 POLYMERASE CHAIN REACTION

10.5.2 ISOTHERMAL AMPLIFICATION

10.6 HOMECARE

10.6.1 POLYMERASE CHAIN REACTION

10.6.2 ISOTHERMAL AMPLIFICATION

10.7 ASSISTED LIVING FACILITIES

10.7.1 POLYMERASE CHAIN REACTION

10.7.2 ISOTHERMAL AMPLIFICATION

10.8 OTHERS

11 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING

11.1 OVERVIEW

11.2 PRESCRIPTION-BASED TESTING

11.3 OTC TESTING

12 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACY

12.3 RETAIL PHARMACY

12.4 ONLINE PHARMACY

13 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION

13.1 EUROPE

13.1.1 U.K.

13.1.2 GERMANY

13.1.3 ITALY

13.1.4 FRANCE

13.1.5 SPAIN

13.1.6 REST OF EUROPE

14 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 DANAHER

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 THERMO FISHER SCIENTIFIC INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 BD

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 F.HOFFMANN-LA-ROCHE LTD.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 ABBOTT

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 BINX HEALTH, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 BIOMERIEUX SA

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 CO-DIAGNOSTICS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 GENMARK DIAGNOSTICS, INC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 GRIFOLS, S.A.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 LUCIRA HEALTH INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 MERIDIAN BIOSCIENCE

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 QUANTUMDX GROUP LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 QUIDEL CORPORATION

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 SD BIOSENSOR, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 WONDFO

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表格列表

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 8 DISTRIBUTORS ACROSS EUROPE

TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 12 DISTRIBUTORS ACROSS AFRICA

TABLE 13 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 14 EUROPE CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 EUROPE INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 EUROPE INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 17 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 18 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 20 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 EUROPE SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 22 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 24 EUROPE OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 26 EUROPE LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 28 EUROPE HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 30 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 32 EUROPE AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 EUROPE AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 34 EUROPE HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 36 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 38 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 40 EUROPE PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 41 EUROPE OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 EUROPE HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 EUROPE RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 EUROPE ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 48 EUROPE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 49 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 50 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 51 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 52 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 53 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 EUROPE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 55 EUROPE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 56 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 57 EUROPE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 58 EUROPE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 59 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 60 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 61 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 62 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 63 U.K. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 64 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 65 U.K. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 66 U.K. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 67 U.K. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 68 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 69 U.K. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 70 U.K. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 71 U.K. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 72 U.K. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 73 U.K. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 74 U.K. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 75 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 76 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 77 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 78 GERMANY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 79 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 80 GERMANY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 81 GERMANY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 82 GERMANY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 83 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 84 GERMANY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 85 GERMANY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 GERMANY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 87 GERMANY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 88 GERMANY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 89 GERMANY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 90 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 92 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 93 ITALY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 94 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 95 ITALY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 96 ITALY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 97 ITALY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 98 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 ITALY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 100 ITALY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 101 ITALY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 102 ITALY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 103 ITALY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 104 ITALY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 105 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 106 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 107 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 108 FRANCE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 109 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 110 FRANCE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 111 FRANCE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 112 FRANCE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 113 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 114 FRANCE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 115 FRANCE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 116 FRANCE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 117 FRANCE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 118 FRANCE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 119 FRANCE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 120 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 121 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 122 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 123 SPAIN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 124 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 125 SPAIN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 126 SPAIN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 127 SPAIN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 129 SPAIN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 130 SPAIN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 131 SPAIN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 132 SPAIN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 133 SPAIN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 134 SPAIN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 135 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 136 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 137 REST OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 2 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS

FIGURE 4 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING

FIGURE 8 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID

FIGURE 11 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD

FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028

FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE MOLECULAR POINT OF CARE TESTING (USING NAAT) MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

FIGURE 17 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 18 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020

FIGURE 19 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 20 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 21 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 22 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020

FIGURE 23 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 24 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 25 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 26 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020

FIGURE 27 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 28 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)

FIGURE 29 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020

FIGURE 31 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)

FIGURE 32 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)

FIGURE 33 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE

FIGURE 34 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 36 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 39 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 40 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 43 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Europe Molecular Point of Care Testing (using NAAT) Market will grow at a CAGR of 10.8% by forecast.
HIGH COST OF PRODUCTS, and LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES are poised to restrict the Europe Molecular Point of Care Testing (using NAAT) Market growth.
The major players operating in the Europe Molecular Point of Care Testing (using NAAT) Market are SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, binx Health, Inc., Lucira, Meridian Bioscience, Quantumdx Group Ltd., BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., Sekisui Diagnostic, Randox Laboratories Ltd., GenMark Diagnostics, Seegene Inc. Grifols S.A., Wondfo, Oxford Nanopore Diagnostic, and PerkinElmer Inc.
The major countries covered in the Europe Molecular Point of Care Testing (using NAAT) Market are U.K., Germany, France, Italy, Spain and the Rest of Europe.